Clinical Trial Update: Intercostal Liposomal Bupivacaine for the Management of Blunt Chest Wall Trauma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating intercostal liposomal bupivacaine for pain management in blunt chest wall trauma shows completed status with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Blunt Chest Wall Trauma
• Rib Fracture
• Sternal Fracture

Drugs mentioned

• Liposomal bupivacaine (bupivacaine liposome injectable suspension)

Snippet

Sponsor: University of Cincinnati | Conditions: Blunt Chest Wall Trauma, Rib Fracture | Phase 2 | Status: COMPLETED | Results posted: 2022-04-04